Avita Medical Stockholders Approve Key Amendments and Elections

The latest announcement is out from Avita Medical ( (RCEL) ).

On June 4, 2025, Avita Medical, Inc. held its Annual Meeting of Stockholders via webcast, where key decisions were made. Stockholders approved amendments to the 2020 Omnibus Incentive Plan, increasing the shares available for issuance by 2,500,000, and approved equity awards for directors and the CEO. Additionally, all proposed directors were elected, Grant Thornton LLP was ratified as the independent auditor, and compensation for executive officers was endorsed, reflecting strong shareholder support for the company’s strategic initiatives.

The most recent analyst rating on (RCEL) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Avita Medical stock, see the RCEL Stock Forecast page.

Spark’s Take on RCEL Stock

According to Spark, TipRanks’ AI Analyst, RCEL is a Neutral.

Avita Medical’s stock score reflects a blend of strong revenue growth and technical momentum, offset by severe profitability challenges and high financial leverage. While future revenue projections and product expansions are promising, underlying financial weaknesses and valuation concerns present significant risks.

To see Spark’s full report on RCEL stock, click here.

More about Avita Medical

Avita Medical, Inc. operates in the medical technology industry, focusing on regenerative medicine solutions. The company is known for its innovative products that aid in skin regeneration and healing, primarily targeting the healthcare sector.

Average Trading Volume: 251,299

Technical Sentiment Signal: Sell

Current Market Cap: $154.9M

Learn more about RCEL stock on TipRanks’ Stock Analysis page.